Lantheus (NASDAQ:LNTH) Issues Q2 Earnings Guidance


Share on StockTwits

Lantheus (NASDAQ:LNTH) issued an update on its second quarter earnings guidance on Tuesday morning. The company provided EPS guidance of $0.03 to $0.06 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.04. The company issued revenue guidance of $93 million to $97 million, compared to the consensus revenue estimate of $93.26 million.Lantheus also updated its FY 2021 guidance to 0.360-0.410 EPS.

Shares of LNTH stock traded down $0.79 during trading on Tuesday, hitting $22.89. 936,570 shares of the company were exchanged, compared to its average volume of 556,573. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.79 and a current ratio of 2.25. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of 286.16 and a beta of 1.32. The business’s 50-day simple moving average is $21.27 and its 200 day simple moving average is $16.75. Lantheus has a twelve month low of $10.52 and a twelve month high of $24.26.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Tuesday, May 4th. The medical equipment provider reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.06. The business had revenue of $92.51 million during the quarter, compared to analysts’ expectations of $87.24 million. Lantheus had a net margin of 0.12% and a return on equity of 11.05%. The firm’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same period last year, the company posted $0.36 earnings per share. On average, equities analysts forecast that Lantheus will post 0.29 earnings per share for the current fiscal year.

A number of analysts have issued reports on LNTH shares. Credit Suisse Group lifted their target price on shares of Lantheus from $14.00 to $17.00 and gave the company a neutral rating in a research note on Thursday, March 4th. Zacks Investment Research upgraded shares of Lantheus from a sell rating to a hold rating in a research note on Wednesday, April 28th. Finally, SVB Leerink boosted their target price on shares of Lantheus from $26.00 to $31.00 and gave the stock an outperform rating in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $25.67.

In other Lantheus news, CEO Mary Anne Heino sold 27,157 shares of the business’s stock in a transaction on Friday, March 5th. The shares were sold at an average price of $18.26, for a total value of $495,886.82. Following the sale, the chief executive officer now owns 711,720 shares of the company’s stock, valued at approximately $12,996,007.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael P. Duffy sold 1,737 shares of the business’s stock in a transaction on Thursday, March 4th. The shares were sold at an average price of $18.40, for a total transaction of $31,960.80. The disclosure for this sale can be found here. Insiders sold a total of 72,188 shares of company stock worth $1,411,148 in the last three months. Insiders own 2.08% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation.

Read More: What is a Fibonacci Channel?

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.